Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Wednesday broker round-up

Wed, 22nd Jan 2020 12:52

(Sharecast News) - Experian: Morgan Stanley upgrades to overweight with a target price of 2,950p.

Rio Tinto: Goldman Sachs reiterates buy with a target price of 4,900p.

Fuller Smith & Turner: Peel Hunt reiterates add with a target price of 1,050p.

AstraZeneca: Liberum reiterates buy with a target price of 8,810p.

GlaxoSmithKline: Liberum reiterates hold with a target price of 1,930p.

easyJet: Deutsche Bank reiterates hold with a target price of 1,540p.

Hays: Liberum downgrades to hold with a target price of 160p.

Victrex: UBS downgrades to sell with a target price of 2,250p.

Pets At Home: Liberum reiterates buy with a target price of 330p.

Imperial Brands: JP Morgan reiterates neutral with a target price of 2,100p.

Ferguson: UBS upgrades to buy with a target price of 8,075p.

Travis Perkins: UBS downgrades to sell with a target price of 1,400p.

Unilever: Berenberg downgrades to hold with a target price of 4,750p.

Related Shares

More News
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announ...

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.